KR101179312B1 - 1-(-ｄ-글리코피라노실)-3-(4-시클로프로필페닐메틸)-4-할로게노 인돌 유도체 및 그의 ｓｇｌｔ 억제제로서의 용도 - Google Patents

1-(-ｄ-글리코피라노실)-3-(4-시클로프로필페닐메틸)-4-할로게노 인돌 유도체 및 그의 ｓｇｌｔ 억제제로서의 용도 Download PDF

Info

Publication number
KR101179312B1
KR101179312B1 KR1020097004110A KR20097004110A KR101179312B1 KR 101179312 B1 KR101179312 B1 KR 101179312B1 KR 1020097004110 A KR1020097004110 A KR 1020097004110A KR 20097004110 A KR20097004110 A KR 20097004110A KR 101179312 B1 KR101179312 B1 KR 101179312B1
Authority
KR
South Korea
Prior art keywords
compound
formula
agent
compounds
cyclopropylphenylmethyl
Prior art date
Application number
KR1020097004110A
Other languages
English (en)
Korean (ko)
Other versions
KR20090040356A (ko
Inventor
수미히로 노무라
시게끼 사까마끼
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101179312(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Publication of KR20090040356A publication Critical patent/KR20090040356A/ko
Application granted granted Critical
Publication of KR101179312B1 publication Critical patent/KR101179312B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020097004110A 2006-07-27 2007-07-27 1-(-ｄ-글리코피라노실)-3-(4-시클로프로필페닐메틸)-4-할로게노 인돌 유도체 및 그의 ｓｇｌｔ 억제제로서의 용도 KR101179312B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82060406P 2006-07-27 2006-07-27
US60/820,604 2006-07-27
US88617807P 2007-01-23 2007-01-23
US60/886,178 2007-01-23
PCT/JP2007/065213 WO2008013322A1 (en) 2006-07-27 2007-07-27 1- (-d-glycopyranosyl) - 3 - (4-cyclopropylphenylmethyl) - 4 - halogeno indole derivatives and use thereof as sglt inhibitors.

Publications (2)

Publication Number Publication Date
KR20090040356A KR20090040356A (ko) 2009-04-23
KR101179312B1 true KR101179312B1 (ko) 2012-09-03

Family

ID=38515468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097004110A KR101179312B1 (ko) 2006-07-27 2007-07-27 1-(-ｄ-글리코피라노실)-3-(4-시클로프로필페닐메틸)-4-할로게노 인돌 유도체 및 그의 ｓｇｌｔ 억제제로서의 용도

Country Status (31)

Country Link
US (1) US7851617B2 (pt)
EP (1) EP2049557B1 (pt)
JP (1) JP5102294B2 (pt)
KR (1) KR101179312B1 (pt)
CN (1) CN101501053B (pt)
AR (1) AR062111A1 (pt)
AT (1) ATE501159T1 (pt)
AU (1) AU2007277662B2 (pt)
BR (1) BRPI0715369A2 (pt)
CA (1) CA2658116C (pt)
CL (1) CL2007002197A1 (pt)
CO (1) CO6150170A2 (pt)
CR (1) CR10583A (pt)
DE (1) DE602007013056D1 (pt)
DK (1) DK2049557T3 (pt)
EA (1) EA016819B1 (pt)
GT (1) GT200900014A (pt)
HN (1) HN2009000161A (pt)
IL (1) IL196267A0 (pt)
JO (1) JO2681B1 (pt)
MX (1) MX2009000995A (pt)
MY (1) MY145106A (pt)
NO (1) NO20085337L (pt)
NZ (1) NZ574072A (pt)
PE (1) PE20080522A1 (pt)
PL (1) PL2049557T3 (pt)
PT (1) PT2049557E (pt)
TW (1) TWI418556B (pt)
UA (1) UA92100C2 (pt)
UY (1) UY30506A1 (pt)
WO (1) WO2008013322A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070609A1 (en) * 2006-12-04 2008-06-12 Janssen Pharmaceutica N.V. Thienyl-containing glycopyranosyl derivatives as antidiabetics
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
PE20110288A1 (es) 2008-08-28 2011-05-26 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2416459T3 (es) 2009-07-10 2013-08-01 Janssen Pharmaceutica, N.V. Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
IN2012DN02711A (pt) * 2009-09-15 2015-09-11 Janssen Pharmaceutica Nv
DK2488515T3 (en) * 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
EP2491050A2 (en) 2009-10-20 2012-08-29 Novartis AG Glycoside derivative and uses thereof
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PT2658844T (pt) 2010-12-28 2017-01-24 Sanofi Sa Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
FR2969614A1 (fr) * 2010-12-28 2012-06-29 Sanofi Aventis Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PT2697218T (pt) 2011-04-13 2016-07-13 Janssen Pharmaceutica Nv Processo para preparação de compostos úteis como inibidores da sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
EP2712360B1 (en) * 2011-05-20 2017-04-12 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibittors of sglt-2
EP2712359B1 (en) * 2011-05-20 2017-06-21 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt-2
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013090550A1 (en) * 2011-12-15 2013-06-20 National Health Research Institutes Novel glycoside compounds
TWI633113B (zh) 2013-10-17 2018-08-21 美國禮來大藥廠 新穎脲化合物
AR098134A1 (es) * 2013-11-01 2016-05-04 Lilly Co Eli Compuestos de urea
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP7137318B2 (ja) * 2018-02-22 2022-09-14 オルガノ株式会社 被処理液の精製方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100728085B1 (ko) 1999-10-12 2007-06-14 브리스톨-마이어스스퀴브컴파니 Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
TR200202200T2 (tr) 2000-03-17 2002-12-23 Kissei Pharmaceutical Co., Ltd. Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler.
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
SI1354888T1 (sl) * 2000-12-28 2009-10-31 Kissei Pharmaceutical Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih
CA2438593C (en) * 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4147111B2 (ja) 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1385856B1 (en) * 2001-04-11 2006-02-22 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
CA2445346C (en) * 2001-04-27 2010-04-06 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
CA2478889A1 (en) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004019958A1 (ja) 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI310033B (en) 2003-03-14 2009-05-21 Yamanouchi Pharma Co Ltd C-glycoside derivatives or salts thereof
WO2005012318A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
SI1651658T2 (sl) 2003-08-01 2020-12-31 Mitsubishi Tanabe Pharma Corporation Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
CA2549022A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
RS20060320A (en) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
UA86042C2 (en) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EP1803729A4 (en) 2004-09-29 2008-10-01 Kissei Pharmaceutical HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008050353A (ja) * 2006-07-27 2008-03-06 Mitsubishi Tanabe Pharma Corp 医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100728085B1 (ko) 1999-10-12 2007-06-14 브리스톨-마이어스스퀴브컴파니 Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제

Also Published As

Publication number Publication date
UA92100C2 (uk) 2010-09-27
MX2009000995A (es) 2009-02-04
TW200811149A (en) 2008-03-01
HN2009000161A (es) 2011-05-25
PT2049557E (pt) 2011-05-05
AR062111A1 (es) 2008-10-15
DK2049557T3 (da) 2011-06-14
EP2049557B1 (en) 2011-03-09
BRPI0715369A2 (pt) 2013-06-18
WO2008013322A1 (en) 2008-01-31
JP5102294B2 (ja) 2012-12-19
AU2007277662A1 (en) 2008-01-31
NZ574072A (en) 2011-05-27
JO2681B1 (en) 2013-03-03
CN101501053B (zh) 2012-10-03
CA2658116C (en) 2011-07-19
CA2658116A1 (en) 2008-01-31
KR20090040356A (ko) 2009-04-23
PE20080522A1 (es) 2008-06-13
UY30506A1 (es) 2008-01-31
DE602007013056D1 (de) 2011-04-21
EA016819B1 (ru) 2012-07-30
EA200970161A1 (ru) 2009-06-30
PL2049557T3 (pl) 2011-07-29
CO6150170A2 (es) 2010-04-20
EP2049557A1 (en) 2009-04-22
TWI418556B (zh) 2013-12-11
US7851617B2 (en) 2010-12-14
JP2009544693A (ja) 2009-12-17
IL196267A0 (en) 2009-09-22
GT200900014A (es) 2010-02-09
CL2007002197A1 (es) 2008-02-15
CR10583A (es) 2009-06-05
US20080027122A1 (en) 2008-01-31
MY145106A (en) 2011-12-30
AU2007277662B2 (en) 2011-02-03
CN101501053A (zh) 2009-08-05
ATE501159T1 (de) 2011-03-15
NO20085337L (no) 2009-04-24

Similar Documents

Publication Publication Date Title
KR101179312B1 (ko) 1-(-ｄ-글리코피라노실)-3-(4-시클로프로필페닐메틸)-4-할로게노 인돌 유도체 및 그의 ｓｇｌｔ 억제제로서의 용도
KR101259198B1 (ko) 인돌 유도체
EP1654269B1 (en) Novel compounds
NO334706B1 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser av slike forbindelser, samt fremgangsmåter for fremstilling av nevnte forbindelser
EP2046346A1 (en) Novel sglt inhibitors
WO2006054629A1 (ja) １－置換－３－（β－Ｄ－グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
WO2008044762A1 (fr) Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
JP2013177462A (ja) 医薬組成物
JP2008050353A (ja) 医薬組成物
US7935674B2 (en) Indole derivatives
ES2358231T3 (es) Derivados de 1-(d-glicopiranosil)-3-(4-ciclopropilfenilmetil)-4-halógeno indol y su uso como inhibidores de sglt.

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20150730

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee